Juan Diego Maya
Faculty of Medicine, University of Chile, ICBM, Program of Molecular and Clinical Pharmacology, P.O. Box 70000 Santiago 7, Chile
Antonio Morello
Faculty of Medicine, University of Chile, ICBM, Program of Molecular and Clinical Pharmacology, P.O. Box 70000 Santiago 7, Chile
ABSTRACT
Chagas’ disease is a major parasitic cause of death and hardship, especially in the impoverished regions of Latin America. Trypanosoma cruzi is the etiologic agent of this disease. Characteristically, this hemoflagellate has an indirect life cycle with mammals as definitive hosts where attacks the heart, skeletal, smooth and cardiac muscles and the central nervous system. The drugs currently in use to treat this disease are nifurtimox and benznidazole. However, they have many side effects and are potentially toxic. Their mode of action includes free radical and electrophilic metabolites generation, which are toxic for the parasite. The parasite is more sensitive to the oxidative stress than the host. Gutathione and its spermidine derivative, trypanothione are the main antioxidative mechanisms in the parasite. Any modification in the parasite capacity to synthesise this thiols could induce a more susceptible environment to the action of the trypanocidal drugs. This effect may shorten treatment length or lower the required doses to treat this disease.
PDF References Citation
How to cite this article
Juan Diego Maya and Antonio Morello, 2005. Inhibition of Glutathione Synthesis as a Potential Therapeutic Strategy Against Chagas’ Disease. Journal of Biological Sciences, 5: 847-854.
DOI: 10.3923/jbs.2005.847.854
URL: https://scialert.net/abstract/?doi=jbs.2005.847.854
DOI: 10.3923/jbs.2005.847.854
URL: https://scialert.net/abstract/?doi=jbs.2005.847.854
REFERENCES
- Amino, R., R.M. Martins, J. Procopio, I.Y. Hirata and M.A. Juliano et al., 2002. Trialysin a novel pore-forming protein from saliva of hematophagous insects activated by limited proteolysis. J. Biol. Chem., 277: 6207-6213.
Direct Link - Prata, A., 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis., 1: 92-100.
PubMedDirect Link - Calvo Mendez, M.L., B. Nogueda Torres and R. Alejandre Aguilar, 1992. The oral route an access port for Trypasonosoma cruz. Rev. Latinoam. Microbiol., 34: 39-42.
Direct Link - Castro, J.A. and E.G. Diaz-de-Toranzo, 1988. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed. Environ. Sci., 1: 19-33.
PubMedDirect Link - Zahoor, A, M.V. Lafleur, R.C. Knight, H. Loman and D.I. Edwards, 1987. DNA damage induced by reduced nitroimidazole drugs. Biochem. Pharmacol., 36: 3299-3304.
PubMedDirect Link - La-Scalea, M.A., S.H. Serrano, E.I. Ferreira and A.M. Brett, 2002. Voltammetric behavior of Benznidazole at a DNA-electrochemical biosensor. J. Pharm. Biomed. Anal., 29: 561-568.
Direct Link - Maya, J.D., S. Bollo, L.J.N. Vergara, J.A. Squella and Y. Repetto et al., 2003. Trypasonosoma cruziEffect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol., 65: 999-1006.
CrossRef - Gutteridge, J.M.C. and B. Halliwell, 2000. Free radicals and antioxidants in the year 2000: A historical look to the future. Ann. N. Y. Acad. Sci., 899: 136-147.
CrossRefDirect Link - Park, J.D., Y. Liu and C.D. Klaassen, 2001. Protective effect of metallothionein against the toxicity of cadmium and other metals (1). Toxicol., 163: 93-100.
CrossRef - Viarengo, A., B. Burlando, N. Ceratto and I. Panfoli, 2000. Antioxidant role of metallothioneins a comparative overview. Cell Mol. Biol., 46: 407-417.
Direct Link - Turrens, J.F., 2004. Oxidative stress and antioxidant defenses a target for the treatment of diseases caused by parasitic protozoa. Mol. Aspects. Med., 25: 211-220.
Direct Link - Wilkinson, S.R. and J.M. Kell, 2003. The role of glutathione peroxidases in trypanosomatids. Biol. Chem., 384: 517-525.
Direct Link - Sies, H., 1999. Glutathione and its role in cellular functions. Free Radic. Biol. Med., 27: 916-921.
CrossRefPubMedDirect Link - Eaton, D.L., 2000. Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicol., 21: 101-111.
PubMedDirect Link - Pourahmad, J. and P.J. O'Brien, 2000. A comparison of hepatocyte cytotoxic mechanisms for Cu2+ and Cd2+. Toxicology, 143: 263-273.
CrossRefPubMedDirect Link - Mazur, L., 2000. Radioprotective effects of the thiols GSH and WR-2721 against X-ray-induction of micronuclei in erythroblasts. Mutat. Res., 468: 27-33.
CrossRef - Hayes, J.D. and L.I. McLellan, 1999. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radical Res., 31: 273-300.
CrossRefDirect Link - Kuhn, H. and A. Borchert, 2002. Regulation of enzymatic lipid peroxidation the interplay of peroxidizing and peroxide reducing enzymes. Free Radic. Biol. Med., 33: 154-172.
Direct Link - Fairlamb, A.H. and A. Cerami, 1985. Identification of a novel thiol-containing co-factor essential for glutathione reductase enzyme activity in trypanosomatids. Mol. Biochem. Parasitol., 14: 187-198.
PubMedDirect Link - Siegel, R.L.K., S.K. Meiering and H. Schmidt, 2003. The parasite-specific trypanothionee metabolism of trypanosoma and leishmania. Biol. Chem., 384: 539-549.
PubMedDirect Link - Griffith, O.W., 1999. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med., 27: 922-935.
Direct Link - Anderson, M.E., 1998. Glutathione: An overview of biosynthesis and modulation. Chem. Biol. Interac., 111-112: 1-14.
CrossRefDirect Link - Fairlamb, A.H. and A. Cerami, 1992. Metabolism and functions of trypanothionee in the Kinetoplastida. Annu. Rev. Microbiol., 46: 695-729.
PubMedDirect Link - Steenkamp, D.J., 2002. Trypanosomal antioxidants and emerging aspects of redox regulation in the trypanosomatids. Antioxid Redox Signal, 4: 105-121.
PubMedDirect Link - Siegel, R.L.K. and H. Ludemann, 1996. Reduction of dehydroascorbate by trypanothionee. Mol. Biochem. Parasitol., 80: 203-208.
PubMedDirect Link - Thomson, L., A. Denicola and R. Radi, 2003. The trypanothionee-thiol system in Trypasonosoma cruz as a key antioxidant mechanism against peroxynitrite-mediated cytotoxicity. Arch. Biochem. Biophys., 412: 55-64.
Direct Link - Cerecetto, H. and M. Gonzalez, 2002. Chemotherapy of Chagas' disease status and new developments. Curr. Top. Med. Chem., 2: 1187-1213.
PubMedDirect Link - Urbina, J.A. and R. Docampo, 2003. Specific chemotherapy of chagas disease controversies and advances. Trends Parasitol., 19: 495-501.
PubMedDirect Link - Eakin, A.E., A. Guerra, P.J. Focia, J. Torres-Martinez and S.P. Craig, 1997. Hypoxanthine phosphoribosyltransferase from Trypasonosoma cruzi as a target for structure-based inhibitor design: Crystallization and inhibition studies with purine analogs. Antimicrob. Agents Chemother., 41: 1686-1692.
PubMed - Araujo, M.S., O.A. Martins-Filho, M.E. Pereira and Z. Brener, 2000. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother., 45: 819-824.
Direct Link - Tapia, R.A., C. Salas, A. Morello, J.D. Maya and A.T. Labbe, 2004. Synthesis of dihydronaphthofurandiones and dihydrofuroquinolinediones with trypanocidal activity and analysis of their stereoelectronic properties. Bioorg. Med. Chem., 12: 2451-2458.
Direct Link - Fekete, I., O.W. Griffith, K.E. Schlageter, D.D. Bigner and H.S. Friedman et al., 1990. Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas. Cancer Res., 50: 1251-1256.
Direct Link - Hibi, T., H. Hisada, T. Nakatsu, H. Kato and J. Oda, 2002. Escherichia coli B gamma-glutamylcysteine synthetase modification purification crystallization and preliminary crystallographic analysis. Acta. Crystallogr D Biol. Crystallogr., 58: 316-318.
Direct Link - Grondin, K., A. Haimeur, R. Mukhopadhyay, B.P. Rosen and M. Ouellette, 1997. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J., 16: 3057-3065.
CrossRef - Grondin, K., A. Haimeur, R. Mukhopadhyay, B.P. Rosen and M. Ouellette, 1997. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J., 16: 3057-3065.
CrossRef - Hussein, A.S. and R.D. Walter, 1995. Purification and characterization of γ-glutamylcysteine synthetase from Ascaris suum. Mol. Biochem. Parasitol., 72: 57-64.
CrossRefDirect Link - Campbell, E.B., M.L. Hayward and O.W. Griffith, 1991. Analytical and preparative separation of the diastereomers of L-buthionine (SR)-sulfoximine a potent inhibitor of glutathione biosynthesis. Annual Biochem., 194: 268-277.
Direct Link - Misra, I. and O.W. Griffith, 1998. Expression and purification of human gamma-glutamylcysteine synthetase. Protein Expr. Purif., 13: 268-276.
Direct Link - Arrick, B.A., O.W. Griffith and A. Cerami, 1981. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J. Exp. Med., 153: 720-725.
Direct Link - Keppler, D., 1999. Export pumps for glutathione S-conjugates. Free Radic. Biol. Med., 27: 985-991.
CrossRef - Chen, X., G.D. Carystinos and G. Batist, 1998. Potential for selective modulation of glutathione in cancer chemotherapy. Chem. Biol. Interact., 111-112: 263-275.
CrossRef - Meister, A. and O.E. Griffith, 1979. Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione possible chemotherapeutic implications. Cancer Treat. Rep., 63: 1115-1121.
Direct Link - Calvert, P., K.S. Yao, T.C. Hamilton and P.J. O'Dwyer, 1998. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact., 111-112: 213-224.
PubMed - Anderson, C.P. and C.P. Reynolds, 2002. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant, 30: 135-140.
CrossRef - Anderson, C.P., R.C. Seeger, N. Satake, H.L. Monforte-Munoz , N. Keshelava et al., 2001. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J. Pediatr. Hematol. Oncol., 23: 500-505.
Direct Link